Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Heart Failure Drug Development Might Need A Good Lawyer After US FDA Guidance

Executive Summary

With draft guidance allowing for drugs that improve heart failure symptoms but do not improve – or may even decrease – survival, the legal community could help establish development metrics.

You may also be interested in...



Bladder Cancer: More Questions Than Answers With pCR Endpoint

Pathologic complete response eventually may be a surrogate endpoint for survival, but researchers and the US FDA outlined several problems that must be resolved first.

Real-World Evidence: When Is Missing Data Not Really 'Missing'?

The concept of missing data is very different when analyzing real-world evidence compared to a randomized clinical trial.

US FDA Searches For Consistency On Assessment Of Real-World Evidence

As more sponsors begin using RWE, the agency is establishing procedures and training to ensure assessors consistently apply policies.

Related Content

Topics

UsernamePublicRestriction

Register

PS140709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel